Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Gastroenterol Hepatol. 2013 Aug;11(8):982-7. doi: 10.1016/j.cgh.2013.02.021. Epub 2013 Mar 1.

Saccharomyces boulardii does not prevent relapse of Crohn's disease.

Author information

1
Institut des Maladies de l'Appareil Digestif (IMAD), Gastroenterology Department, CIC, Inserm-04, CHU, University Hospital, Nantes, France. arnaud.bourreille@chu-nantes.fr

Abstract

BACKGROUND & AIMS:

Saccharomyces boulardii is a probiotic yeast that has been shown to have beneficial effects on the intestinal epithelial barrier and digestive immune system. There is preliminary evidence that S boulardii could be used to treat patients with Crohn's disease (CD). We performed a randomized, placebo-controlled trial to evaluate the effects of S boulardii in patients with CD who underwent remission during therapy with steroids or aminosalicylates.

METHODS:

We performed a prospective study of 165 patients who achieved remission after treatment with steroids or salicylates; they were randomly assigned to groups given S boulardii (1 g/day) or placebo for 52 weeks. The primary end point was the percentage of patients in remission at week 52. Time to relapse, Crohn's disease activity index scores, and changes in parameters of inflammation were secondary end points.

RESULTS:

CD relapsed in 80 patients, 38 in the S boulardii group (47.5%) and 42 in the placebo group (53.2%, a nonsignificant difference). The median time to relapse did not differ significantly between patients given S boulardii (40.7 weeks) vs placebo (39.0 weeks). There were no significant differences between groups in mean Crohn's disease activity index scores or erythrocyte sedimentation rates or in median levels of C-reactive protein. In a post hoc analysis, nonsmokers given S boulardii were less likely to experience a relapse of CD than nonsmokers given placebo, but this finding requires confirmation.

CONCLUSIONS:

Although the probiotic yeast S boulardii is safe and well tolerated, it does not appear to have any beneficial effects for patients with CD in remission after steroid or salicylate therapies.

KEYWORDS:

AE; C-reactive protein; CD; CDAI; CI; CRP; Crohn's disease; Crohn's disease activity index; ESR; IBD; Inflammatory Bowel Disease; Maintenance Therapy; Microbiota; OR; PP; adverse event; confidence interval; erythrocyte sedimentation rate; inflammatory bowel disease; mITT; modified intent-to-treat; odds ratio; per-protocol

Comment in

PMID:
23466709
DOI:
10.1016/j.cgh.2013.02.021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center